Carcinoma, Hepatocellular — Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
Citation(s)
The Combination of Pembrolizumab and Lenvatinib as Neoadjuvant Treatment for Hepatocellular Carcinoma Patients: a Single Arm Phase II Study